IL185906D0 - Composition - Google Patents

Composition

Info

Publication number
IL185906D0
IL185906D0 IL185906A IL18590607A IL185906D0 IL 185906 D0 IL185906 D0 IL 185906D0 IL 185906 A IL185906 A IL 185906A IL 18590607 A IL18590607 A IL 18590607A IL 185906 D0 IL185906 D0 IL 185906D0
Authority
IL
Israel
Prior art keywords
composition
Prior art date
Application number
IL185906A
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to GB0506004A priority Critical patent/GB0506004D0/en
Priority to GB0506001A priority patent/GB0506001D0/en
Priority to GB0506000A priority patent/GB0506000D0/en
Priority to GB0505998A priority patent/GB0505998D0/en
Priority to GB0505989A priority patent/GB0505989D0/en
Priority to GB0510596A priority patent/GB0510596D0/en
Priority to GB0510591A priority patent/GB0510591D0/en
Priority to GB0510593A priority patent/GB0510593D0/en
Priority to GB0510598A priority patent/GB0510598D0/en
Priority to GB0510589A priority patent/GB0510589D0/en
Priority to GB0603788A priority patent/GB0603788D0/en
Priority to GB0603790A priority patent/GB0603790D0/en
Priority to GB0603789A priority patent/GB0603789D0/en
Priority to PCT/EP2006/002838 priority patent/WO2006100111A1/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36441219&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL185906(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of IL185906D0 publication Critical patent/IL185906D0/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/145Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55572Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses negative-sense
    • C12N2760/00011MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses negative-sense ssRNA Viruses negative-sense
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses negative-sense
    • C12N2760/00011MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses negative-sense ssRNA Viruses negative-sense
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses negative-sense
    • C12N2760/00011MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses negative-sense ssRNA Viruses negative-sense
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16211Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
IL185906A 2005-03-23 2007-09-11 Composition IL185906D0 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
GB0506004A GB0506004D0 (en) 2005-03-23 2005-03-23 Compositions
GB0506001A GB0506001D0 (en) 2005-03-23 2005-03-23 Novel use
GB0506000A GB0506000D0 (en) 2005-03-23 2005-03-23 Novel use
GB0505998A GB0505998D0 (en) 2005-03-23 2005-03-23 Novel compositions
GB0505989A GB0505989D0 (en) 2005-03-23 2005-03-23 Compositions
GB0510591A GB0510591D0 (en) 2005-05-24 2005-05-24 Novel use
GB0510593A GB0510593D0 (en) 2005-05-24 2005-05-24 Novel compositions
GB0510598A GB0510598D0 (en) 2005-05-24 2005-05-24 Composition
GB0510589A GB0510589D0 (en) 2005-05-24 2005-05-24 Novel use
GB0510596A GB0510596D0 (en) 2005-05-24 2005-05-24 Composition
GB0603790A GB0603790D0 (en) 2006-02-24 2006-02-24 Composition
GB0603789A GB0603789D0 (en) 2006-02-24 2006-02-24 Novel use
GB0603788A GB0603788D0 (en) 2006-02-24 2006-02-24 Novel composition
PCT/EP2006/002838 WO2006100111A1 (en) 2005-03-23 2006-03-21 Composition

Publications (1)

Publication Number Publication Date
IL185906D0 true IL185906D0 (en) 2008-01-06

Family

ID=36441219

Family Applications (3)

Application Number Title Priority Date Filing Date
IL185906A IL185906D0 (en) 2005-03-23 2007-09-11 Composition
IL185897A IL185897A (en) 2005-03-23 2007-09-11 Use of an influenza virus or antigenic preparation thereof from a first influenza strain and an oil-in- water emulsion adjuvant in the preparation of an immunogenic composition for protection against influenza infections caused by a variant influenza strain wherein said oil-in-water emulsion comprises a squalene, alpha-tocopherol and an emulsifying agent
IL185901A IL185901D0 (en) 2005-03-23 2007-09-11 Novel composition

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL185897A IL185897A (en) 2005-03-23 2007-09-11 Use of an influenza virus or antigenic preparation thereof from a first influenza strain and an oil-in- water emulsion adjuvant in the preparation of an immunogenic composition for protection against influenza infections caused by a variant influenza strain wherein said oil-in-water emulsion comprises a squalene, alpha-tocopherol and an emulsifying agent
IL185901A IL185901D0 (en) 2005-03-23 2007-09-11 Novel composition

Country Status (23)

Country Link
US (5) US20090081253A1 (en)
EP (4) EP1863529A1 (en)
JP (4) JP5869744B2 (en)
KR (5) KR20070116651A (en)
AR (3) AR053833A1 (en)
AU (3) AU2006226459A1 (en)
CA (3) CA2603180C (en)
CY (1) CY1117874T1 (en)
DK (1) DK1861120T3 (en)
EA (3) EA011419B1 (en)
ES (1) ES2585810T3 (en)
HR (1) HRP20160816T1 (en)
HU (1) HUE027837T2 (en)
IL (3) IL185906D0 (en)
MA (3) MA30298B1 (en)
MX (3) MX2007011748A (en)
NO (3) NO20074635L (en)
NZ (2) NZ561823A (en)
PE (3) PE14282006A1 (en)
PL (1) PL1861120T3 (en)
PT (1) PT1861120T (en)
TW (3) TW200700078A (en)
WO (3) WO2006100111A1 (en)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1154790E (en) * 1999-02-26 2005-03-31 Chiron Srl Strengthening the bactericidal activity against Neisseria antigens containing CG motifs with oligonucleotides
GB9923176D0 (en) * 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
US20100221284A1 (en) * 2001-05-30 2010-09-02 Saech-Sisches Serumwerk Dresden Novel vaccine composition
WO2006100111A1 (en) * 2005-03-23 2006-09-28 Glaxosmithkline Biologicals S.A. Composition
DE06808434T1 (en) * 2005-11-04 2009-12-17 Novartis Vaccines And Diagnostics S.R.L. Emulsions with free aqueous phases Tensid as adjuvant for gap-flu vaccines
AU2006310340B2 (en) * 2005-11-04 2011-02-10 Novartis Ag Changing TH1/TH2 balance in split influenza vaccines with adjuvants
EP2368572A3 (en) * 2005-11-04 2013-04-24 Novartis Vaccines and Diagnostics S.r.l. Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
EP1951298A1 (en) * 2005-11-04 2008-08-06 Novartis Vaccines and Diagnostics S.r.l. Adjuvanted influenza vaccines including cytokine-inducing agents
EP2086582B1 (en) * 2006-10-12 2012-11-14 GlaxoSmithKline Biologicals s.a. Vaccine comprising an oil in water emulsion adjuvant
BRPI0717219A2 (en) * 2006-10-12 2015-05-26 Glaxosmithkline Biolog Sa "Immunogenic composition, a method for treating or preventing disease, and use of an immunogenic composition."
FR2896162B1 (en) * 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion oil in water thermo
US8420102B2 (en) 2006-03-07 2013-04-16 Vaxinnate Corporation Compositions that include hemagglutinin
CA2646349A1 (en) * 2006-03-24 2007-10-04 Novartis Vaccines And Diagnostics Gmbh & Co Kg Storage of influenza vaccines without refrigeration
EP2032163B1 (en) * 2006-06-15 2013-01-23 Novartis AG Adjuvant-sparing multi-dose influenza vaccination regimen
CA2583555A1 (en) * 2006-07-17 2008-01-17 Glaxosmithkline Biologicals S.A. Influenza vaccine
EP2422810B1 (en) * 2006-07-17 2014-10-22 GlaxoSmithKline Biologicals s.a. Influenza vaccine
WO2008009309A1 (en) 2006-07-17 2008-01-24 Glaxosmithkline Biologicals S.A. Influenza vaccine
PE01462009A1 (en) * 2007-04-20 2009-03-23 Glaxosmithkline Biolog Sa immunogenic composition against influenza virus
GB0622282D0 (en) 2006-11-08 2006-12-20 Novartis Ag Quality control methods
EP1923070A1 (en) * 2006-11-15 2008-05-21 Intervet International BV Vaccine for vaccinating feline against influenza virus
WO2008068631A2 (en) * 2006-12-06 2008-06-12 Novartis Ag Vaccines including antigen from four strains of influenza virus
EP1938835A1 (en) * 2006-12-29 2008-07-02 Pevion Biotech AG Non-specific immunostimulating agents
NZ579262A (en) * 2007-02-23 2012-04-27 Baylor Res Inst Therapeutic applications of activation of human antigen-presenting cells through dectin-1
NZ583377A (en) 2007-10-12 2013-11-29 Csl Ltd Method of eliciting an immune response against pandemic influenza virus
ES2383231T3 (en) 2007-10-19 2012-06-19 Novartis Ag Meningococcal vaccine formulations
EP2227251A1 (en) * 2007-12-06 2010-09-15 GlaxoSmithKline Biologicals SA Influenza composition
TWI376385B (en) * 2007-12-07 2012-11-11 Nat Health Research Institutes Production of lipidated proteins in e. coli
US8466259B2 (en) * 2007-12-07 2013-06-18 National Health Research Institutes Adjuvants
EP2889042A3 (en) * 2008-03-18 2015-10-14 Novartis AG Improvements in preparation of influenza virus vaccine antigens
WO2009128950A2 (en) 2008-04-18 2009-10-22 Vaxinnate Corporation Deletion mutants of flagellin and methods of use
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
CA2729248A1 (en) 2008-06-25 2009-12-30 Novartis Ag Rapid responses to delayed booster immunisations
EP2396032B1 (en) 2009-02-10 2016-09-28 Seqirus UK Limited Influenza vaccines with reduced amounts of squalene
ES2552383T3 (en) 2009-02-10 2015-11-27 Novartis Ag Regimens for influenza vaccine strains associated pandemics
AU2015203072B2 (en) * 2009-02-10 2017-05-25 Seqirus UK Limited Influenza vaccine regimens for pandemic-associated strains
GB0905570D0 (en) * 2009-03-31 2009-05-13 Novartis Ag Combined vaccines
US8287880B2 (en) * 2009-06-02 2012-10-16 National Health Research Institutes Lipidated vaccine against dengue virus infection
EP2445927B1 (en) * 2009-06-22 2014-04-23 National Health Research Institutes Lipidated tumor- associated antigens and immunotherapeutic compositions
EP2289575B1 (en) * 2009-08-06 2017-07-05 Biotronik VI Patent AG Medical implant containing an antioxidative substance
EP2308506A1 (en) * 2009-10-02 2011-04-13 Mucosis B.V. Adjuvanted intranasal vaccine formulations
GB0918830D0 (en) 2009-10-27 2009-12-09 Glaxosmithkline Biolog Niederl Process
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
JP5820390B2 (en) 2009-12-03 2015-11-24 ノバルティス アーゲー Circulation of components in microfluidized emulsions and / or homogenization in
USRE46906E1 (en) 2009-12-03 2018-06-26 Novartis Ag Methods for producing vaccine adjuvants
DE102009056883B4 (en) 2009-12-03 2012-08-16 Novartis Ag Vaccine adjuvants and to improved processes for the preparation thereof
US20130189311A1 (en) * 2009-12-03 2013-07-25 Novartis Ag Arranging interaction and back pressure chambers for microfluidization
DE102009056871A1 (en) 2009-12-03 2011-06-22 Novartis AG, 4056 Vaccine adjuvants and to improved processes for the preparation thereof
DE102009056884A1 (en) 2009-12-03 2011-06-09 Novartis Ag Vaccine adjuvants and to improved processes for the preparation thereof
CA2780425C (en) * 2009-12-03 2014-02-04 Novartis Ag Hydrophilic filtration during manufacture of vaccine adjuvants
AU2013202690B2 (en) * 2009-12-03 2016-02-11 Novartis Ag Hydrophilic filtration during manufacture of vaccine adjuvants
AU2010335970B2 (en) * 2009-12-22 2016-11-03 Sanofi Pasteur Limited Immunogenic compositions
MX2012007916A (en) * 2010-01-06 2012-11-06 Vaxinnate Corp Methods and compositions for providing protective immunity in the elderly.
WO2011088451A1 (en) * 2010-01-15 2011-07-21 Novavax, Inc. Uses of influenza virus-like particles (vlps) for characterization of neuraminidase and hemagglutinin activity
RU2527688C2 (en) * 2010-02-27 2014-09-10 Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" Method of treating infectious diseases caused by influenza virus with type h1n1 surface antigen and therapeutic agent for treating infectious diseases caused by influenza virus with type h1n1 surface antigen
GB201009673D0 (en) 2010-06-10 2010-07-21 Glaxosmithkline Biolog Sa Novel process
GB201009676D0 (en) * 2010-06-10 2010-07-21 Glaxosmithkline Biolog Sa Novel process
GB201009671D0 (en) 2010-06-10 2010-07-21 Glaxosmithkline Biolog Sa Novel process
US9821051B1 (en) 2010-10-28 2017-11-21 Seqirus UK Limited Reducing hospitalization in elderly influenza vaccine recipients
TWI507413B (en) * 2010-11-15 2015-11-11 Nat Health Research Institutes Lipidated polyepitope vaccines
TW201221642A (en) 2010-11-15 2012-06-01 Nat Health Research Institutes Method of producing lipidated polypeptides
JP6247639B2 (en) * 2012-12-28 2017-12-13 国立感染症研究所長 Nasal influenza vaccine composition
US20140335116A1 (en) * 2013-05-10 2014-11-13 Novartis Ag Avoiding narcolepsy risk in influenza vaccines
CN104436157A (en) * 2013-09-23 2015-03-25 恩金生物有限公司 Influenza vaccine and therapy
US10080792B2 (en) * 2013-09-23 2018-09-25 Engen Bio, Inc. Influenza vaccine and therapy

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3095974A (en) * 1961-10-27 1963-07-02 Anthony R Perini Collapsible book rack
US4047869A (en) * 1973-02-23 1977-09-13 Mulvany Jr R F Apparatus for forming plastic articles
FR2333610B1 (en) * 1975-12-03 1978-04-14 Zhdanovsky Z Tyazhelogo Mash
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
DD155875A1 (en) 1980-12-31 1982-07-14 Willy Nordheim A method for producing a fiber-poor inactivated influenza vaccine
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) * 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
DD211444A3 (en) 1982-08-19 1984-07-11 Saechsisches Serumwerk A process for the production of influenza vaccines
GB8300467D0 (en) 1983-01-08 1983-02-09 Wellcome Found Equine influenza
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
DD300833A7 (en) 1985-10-28 1992-08-13 Saechsische Landesgewerbefoerd A process for production of inactivated influenza virus vaccines fully
CA1283827C (en) 1986-12-18 1991-05-07 Giorgio Cirelli Appliance for injection of liquid formulations
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
AU614755B2 (en) 1987-06-05 1991-09-12 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Autocrine motility factors in cancer diagnosis and management
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
DE3734306A1 (en) 1987-10-10 1989-04-27 Pfeiffer Erich Gmbh & Co Kg Discharge for fliessfaehige media
US5376369A (en) * 1987-11-03 1994-12-27 Syntex (U.S.A.) Inc. Vaccine adjuvant
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
GB8821049D0 (en) 1988-09-08 1988-10-05 Health Lab Service Board Method & composition for treatment & prevention of viral infections
FR2638359A1 (en) 1988-11-03 1990-05-04 Tino Dalto syringe guide with adjustment of the penetration depth of the needle into the skin
ES2068989T3 (en) * 1989-02-04 1995-05-01 Akzo Nobel Nv Tocols as adjuvant in vaccines.
US5092235A (en) 1989-05-24 1992-03-03 Tektronix, Inc. Pressure fixing and developing apparatus
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
DE4005528C2 (en) 1990-02-22 1998-01-15 Pfeiffer Erich Gmbh & Co Kg Discharge for Media
US5969109A (en) * 1990-02-28 1999-10-19 Bona; Constantin Chimeric antibodies comprising antigen binding sites and B and T cell epitopes
WO1991013261A1 (en) 1990-03-02 1991-09-05 Experimentalny Nauchno-Issledovatelsky Institut Metallorezhuschikh Stankov Digital servo drive
US5149531A (en) * 1990-06-27 1992-09-22 University Of Pittsburgh Of The Commonwealth System Of Higher Education Method of using cold-adapted live influenza virus vaccine as an antiviral agent against influenza
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
GB9105992D0 (en) 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (en) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
MA22842A1 (en) 1992-03-27 1993-10-01 Smithkline Beecham Biolog vaccine compositions of Preparation Method.
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
EP0684838A1 (en) * 1993-02-19 1995-12-06 SMITHKLINE BEECHAM BIOLOGICALS s.a. Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a
CA2156525A1 (en) 1993-02-19 1994-09-01 Susan Dillon Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a
DE69428136D1 (en) 1993-03-23 2001-10-04 Smithkline Beecham Biolog 3-0 Deazylierte monophosphoryl lipid A containing vaccine compositions
US5762939A (en) * 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
AU5543294A (en) 1993-10-29 1995-05-22 Pharmos Corp. Submicron emulsions as vaccine adjuvants
ES2149340T3 (en) 1993-11-17 2000-11-01 Om Pharma Glucosamine disaccharides, method for their preparation, pharmaceutical composition comprising them, and their use.
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
WO1995022989A1 (en) 1994-02-24 1995-08-31 Micro-Pak, Inc. Vaccines containing paucilamellar lipid vesicles as immunological adjuvants
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
BR9608199B1 (en) 1995-04-25 2009-05-05 vaccine composition comprising an antigen, QS21 and a sterol.
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
US5916879A (en) 1996-11-12 1999-06-29 St. Jude Children's Research Hospital DNA transcription unit vaccines that protect against avian influenza viruses and methods of use thereof
TW570803B (en) 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
CA2302554C (en) * 1997-09-05 2007-04-10 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
IT1298087B1 (en) 1998-01-08 1999-12-20 Fiderm S R L A device for controlling the depth 'of penetration of a needle, in particular applicable to a syringe for injections
AU750720B2 (en) * 1998-03-09 2002-07-25 Smithkline Beecham Biologicals (Sa) Combined vaccine compositions
US6838269B1 (en) * 1998-04-15 2005-01-04 Genencor International, Inc. Proteins producing an altered immunogenic response and methods of making and using the same
AT375803T (en) 1998-05-07 2007-11-15 Corixa Corp Adjuvant and methods for their verwendng
HU0102332A3 (en) 1998-06-08 2002-11-28 Sca Emballage France Fast flattening packaging
ES2284275T3 (en) 1998-06-30 2007-11-01 Om Pharma Acylated pseudodipeptides new, their preparation procedures and pharmaceutical compositions including them.
AT408615B (en) 1998-09-15 2002-01-25 Immuno Ag New influenza virus vaccine composition
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
AT407958B (en) 1999-02-11 2001-07-25 Immuno Ag Inactivated influenza virus vaccine for nasal or oral application
US8206749B1 (en) 1999-02-26 2012-06-26 Novartis Vaccines And Diagnostics, Inc. Microemulsions with adsorbed macromolecules and microparticles
KR20070073987A (en) 2000-01-31 2007-07-10 글락소스미스클라인 바이오로지칼즈 에스.에이. Vaccine for the prophylactic or therapeutic immunization against hiv
FR2796289B1 (en) 1999-07-16 2001-08-10 Cross Site Technologies Needleless syringe with injector stack assembly
FR2796290B1 (en) 1999-07-16 2001-09-14 Cross Site Technologies Needleless syringe operated with a shock wave generator through a wall
FR2796291B1 (en) 1999-07-16 2001-09-21 Cross Site Technologies Needleless syringe provided with a system of triggering PIEZOELECTRIC
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB9921147D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB9923176D0 (en) * 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
US6494865B1 (en) 1999-10-14 2002-12-17 Becton Dickinson And Company Intradermal delivery device including a needle assembly
FR2800619B1 (en) 1999-11-05 2002-02-08 Cross Site Technologies Needleless syringe with a means to temporarily retained thrust
FR2802103B1 (en) 1999-12-08 2003-10-03 Poudres & Explosifs Ste Nale needleless syringe running training of the active substance by impact shock tube
FR2802102B1 (en) 1999-12-08 2002-07-12 Poudres & Explosifs Ste Nale Needleless syringe provided with an ejection tube has constant cross-section
WO2001046127A1 (en) 1999-12-22 2001-06-28 Om Pharma Acyl pseudopeptides bearing a functionalised auxiliary spacer
FR2802820B1 (en) 1999-12-27 2002-10-18 Poudres & Explosifs Ste Nale needleless syringe functioning by impact shock tube, with maintenance of the active ingredient prior to the side
FR2804329B1 (en) 2000-02-02 2002-12-13 Poudres & Explosifs Ste Nale Needleless syringe provided with a cap containing the active principle
FR2804869B1 (en) 2000-02-11 2002-05-17 Poudres & Explosifs Ste Nale A needleless syringe for injecting a liquid contained in a pre-filled ampoule
FR2805749B1 (en) 2000-03-01 2002-05-17 Poudres & Explosifs Ste Nale The needleless syringe has two injection speed levels
FR2807946B1 (en) 2000-04-19 2002-06-07 Poudres & Explosifs Ste Nale needleless syringe operating with a pyrotechnic charge bicomposition
FR2809626B1 (en) 2000-05-30 2003-03-07 Poudres & Explosifs Ste Nale Needleless syringe with insulating membrane an eductor Multichannel
FR2810554B1 (en) 2000-06-22 2003-05-16 Poudres & Explosifs Ste Nale Needleless syringe provided with a modular reservoir
FR2812202B1 (en) 2000-07-28 2002-09-13 Poudres & Explosifs Ste Nale Needleless syringe actuated to compression of the reservoir containing the liquid active principle
US7361352B2 (en) * 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
GB0025577D0 (en) 2000-10-18 2000-12-06 Smithkline Beecham Biolog Vaccine
FR2815544B1 (en) 2000-10-23 2003-02-14 Poudres & Explosifs Ste Nale Securisee syringe without needle compact design
EP1201250A1 (en) 2000-10-25 2002-05-02 Institut Pasteur Immunogenic compositions comprising liver stage malarial antigens
JP5208347B2 (en) * 2001-02-23 2013-06-12 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム The novel vaccine
TWI228420B (en) * 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
US6861410B1 (en) 2002-03-21 2005-03-01 Chiron Corporation Immunological adjuvant compositions
IL164281D0 (en) * 2002-04-01 2005-12-18 Euro Celtique Sa Epitope constructs comprising antigen presenting cell targeting mechanisms
WO2004075829A2 (en) 2003-01-30 2004-09-10 Chiron Corporation Adjuvanted influenza vaccine
US20080254065A1 (en) * 2004-03-09 2008-10-16 Chiron Corporation Influenza Virus Vaccines
WO2006100111A1 (en) * 2005-03-23 2006-09-28 Glaxosmithkline Biologicals S.A. Composition
US20090028903A1 (en) * 2005-03-23 2009-01-29 Glaxosmithkline Biologicals, S.A. Novel use
AR054822A1 (en) 2005-07-07 2007-07-18 Sanofi Pasteur Emulsion immuno adjuvant
EP1951302A2 (en) 2005-11-04 2008-08-06 Novartis Vaccines and Diagnostics S.r.l. Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
BRPI0717219A2 (en) 2006-10-12 2015-05-26 Glaxosmithkline Biolog Sa "Immunogenic composition, a method for treating or preventing disease, and use of an immunogenic composition."
FR2896162B1 (en) 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion oil in water thermo
WO2007130330A2 (en) 2006-05-01 2007-11-15 Technovax, Inc. Polyvalent influenza virus-like particle (vlp) compositions
EP2422810B1 (en) * 2006-07-17 2014-10-22 GlaxoSmithKline Biologicals s.a. Influenza vaccine
WO2008009309A1 (en) * 2006-07-17 2008-01-24 Glaxosmithkline Biologicals S.A. Influenza vaccine
PE01462009A1 (en) * 2007-04-20 2009-03-23 Glaxosmithkline Biolog Sa immunogenic composition against influenza virus
EP2227251A1 (en) * 2007-12-06 2010-09-15 GlaxoSmithKline Biologicals SA Influenza composition

Also Published As

Publication number Publication date
CY1117874T1 (en) 2017-05-17
SI1861120T1 (en) 2016-09-30
US20140363474A1 (en) 2014-12-11
IL185897D0 (en) 2008-01-06
CA2601022A1 (en) 2006-09-28
JP2008534466A (en) 2008-08-28
US20090081253A1 (en) 2009-03-26
DK1861120T3 (en) 2016-07-25
TW200722101A (en) 2007-06-16
EA200701786A1 (en) 2008-04-28
TW200700079A (en) 2007-01-01
NZ561823A (en) 2010-04-30
NO20074930L (en) 2007-12-07
WO2006100110A1 (en) 2006-09-28
NO20074635L (en) 2007-12-19
KR20160064249A (en) 2016-06-07
AU2006226459A1 (en) 2006-09-28
CA2603180C (en) 2015-10-13
US20080181911A1 (en) 2008-07-31
KR20140004815A (en) 2014-01-13
PT1861120T (en) 2016-08-18
MX2007011748A (en) 2008-03-11
PE13872006A1 (en) 2007-01-19
MA30298B1 (en) 2009-04-01
AR054020A1 (en) 2007-05-30
CA2603180A1 (en) 2006-09-28
EP2397153A1 (en) 2011-12-21
WO2006100109A1 (en) 2006-09-28
EA011393B1 (en) 2009-02-27
EP1861122A1 (en) 2007-12-05
PE14282006A1 (en) 2007-01-16
PL1861120T3 (en) 2016-11-30
JP2008534465A (en) 2008-08-28
US20080171063A1 (en) 2008-07-17
KR20070116651A (en) 2007-12-10
JP2008534467A (en) 2008-08-28
EP1863529A1 (en) 2007-12-12
AR052625A1 (en) 2007-03-21
MA29342B1 (en) 2008-03-03
HRP20160816T1 (en) 2016-08-12
IL185897A (en) 2015-11-30
EP1861120B1 (en) 2016-05-25
NZ561822A (en) 2010-04-30
IL185901D0 (en) 2008-01-06
ES2585810T3 (en) 2016-10-10
PE13002006A1 (en) 2006-12-23
AU2006226458A1 (en) 2006-09-28
TW200700078A (en) 2007-01-01
KR101916787B1 (en) 2019-01-24
CA2602456A1 (en) 2006-09-28
EA011419B1 (en) 2009-02-27
US9730999B2 (en) 2017-08-15
AR053833A1 (en) 2007-05-23
KR20070116650A (en) 2007-12-10
EP1861120A1 (en) 2007-12-05
JP5869744B2 (en) 2016-02-24
AU2006226543B2 (en) 2011-10-06
EA200701787A1 (en) 2008-08-29
NO20074638L (en) 2007-12-19
MA29715B1 (en) 2008-09-01
US20110287054A1 (en) 2011-11-24
JP2014129359A (en) 2014-07-10
KR20070116652A (en) 2007-12-10
AU2006226543A1 (en) 2006-09-28
HUE027837T2 (en) 2016-11-28
MX2007011775A (en) 2008-03-11
MX2007011756A (en) 2008-03-11
EA200701785A1 (en) 2008-04-28
WO2006100111A1 (en) 2006-09-28
JP5770414B2 (en) 2015-08-26
AU2006226458B2 (en) 2012-08-30

Similar Documents

Publication Publication Date Title
TWI363053B (en) Pyrazolylcarboxanilides
TWI377134B (en) Sicherheitsdokument
DE602006018441D1 (en) Arabinofuranosidasen
DE602006012366D1 (en) Oximester-photoinitiatoren
DE602006013270D1 (en) Prrs-impfstoffe
DE602006021475D1 (en) Carbonylierungsverfahren
DE602006017073D1 (en) Aspartylproteasehemmer
DE602006005477D1 (en) Imidazopyridinverbindungen
HK1176076A1 (en) Anti-glypican-3 antibody --3
DE602006018627D1 (en) Cholesterol-absorptionsinhibitor
IL185901D0 (en) Novel composition
TWI321562B (en) Novel sulphonylpyrroles
AP2108A (en) Novel biphenylsulfonamides
IL184421D0 (en) Fertilizer-compatible composition
EP1930012A4 (en) Cellooligosaccharide-containing composition
DE602006016093D1 (en) Cyanoanthranilamidinsektizide
TWI358303B (en) Composition
EP1877042A4 (en) Bioenhanced compositions
DE602006009095D1 (en) Diacylglycerol-acyltransferase-hemmer
PL1948770T3 (en) Composition
HK1116776A1 (en) Triazolophthalazines as pde2-inhibitors
DE602006015503D1 (en) Luftreinigeranordnung
TWI382971B (en) Novel sulphonylpyrroles
DE602006020169D1 (en) Differential-bogendraht
TWI379850B (en) Copolyetherimides